

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MedSci Healthcare Holdings Limited

梅斯健康控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2415)

INSIDE INFORMATION POSITIVE PROFIT ALERT

This announcement is made by MedSci Healthcare Holdings Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary review of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2023 and an assessment of the information currently available to the Board, the Group is expected to record a profit attributable to the Shareholders of approximately around RMB10 million for the six months ended 30 June 2023 as compared to a net loss attributable to the Shareholders recorded for the six months ended 30 June 2022. The Group is also expected to record an increase in the adjusted net profit of approximately around 10% to 20% as compared to its adjusted net profit for the six months ended 30 June 2022. The adjusted net profit refers to the net profit of the Group excluding listing related expenses and fair value loss on convertible redeemable preferred shares. The profit turnaround and the increase in the Group’s adjusted net profit were mainly attributable to an increase in net profit from the Group’s provision of precision omni-channel marketing solutions (精準全渠道營銷解決方案) and physician platform solutions (醫師平台解決方案).

As at the date of this announcement, the Company is still in the course of preparing the interim results of the Company for the six months ended 30 June 2023. The information contained in this announcement is only based on the preliminary assessment by the Board

of the unaudited consolidated management accounts of the Company for the six months ended 30 June 2023, which has not been reviewed by the Company's auditors, nor confirmed by the audit committee of the Company. Such financial information will be subject to finalisation and necessary adjustments. The interim results of the Company for the six months ended 30 June 2023 are expected to be announced by the Company on or around 25 August 2023. Shareholders and potential investors are advised to read the interim results announcement of the Company when it is published.

Shareholders and potential investors should exercise caution when dealing in the shares of the Company.

By order of the Board
MedSci Healthcare Holdings Limited
梅斯健康控股有限公司

Dr. Zhang Fabao
Chairman of the Board and Executive Director

Hong Kong, 21 August 2023

As at the date of this announcement, the Board of Directors comprises Dr. Zhang Fabao, Dr. Li Xinmei, Mr. Fan Jie and Mr. Wang Shuai, as executive Directors; Mr. Hu Xubo and Mr. Yan Shengfeng, as non-executive Directors; and Ms. Liu Tao, Mr. Yu Mingyang and Mr. Lau Yiu Kwan Stanley, as independent non-executive Directors.